A mid-size client was preparing for a product launch and needed assistance facilitating a successful go-to-market strategy. The company sought to identify and understand the entire stakeholder landscape and create short- and long-term stakeholder engagement strategies to meet the needs of their entire organization.
A biopharma company engaged Magnolia Market Access and sister company, 81qd, to collect data and segment provider and payer entities to identify key decision
makers for a novel cardiology treatment.
A large pharmaceutical company needed to
demonstrate the potential cost savings of placing a new drug on payer formularies.
Magnolia Market Access has just released its fourth IRA Payer Insights Survey. This chartbook provides an overview of findings from the 34 payers and actuaries surveyed and interviewed regarding the future Medicare Drug Price Netoriation Program, Part D Redesign, and the Medicare Prescription Payment Program.
Navigating Market Access with Magnolia Summer 2024 Presentation.
Magnolia was asked to assess which type of cell therapies and disease states offered the greatest potential for development, and also wanted to further understand the benefits of creating an autologous or allogeneic product.
A new, oral formulation of an existing infused product offered better adherence and less waste, but it was uncertain if these benefits would change payer, provider, and patient pain points or critical success factors for the product’s pricing strategy.
Magnolia was engaged as a payer agency of record for a mental health digital therapeutic. Although the company had experience launching drugs in the U.S. market, the novelty of the digital therapeutic space was challenging, and the company did not have experience in mental health, nor a comprehensive launch plan in place across channels.
Magnolia to evaluated the likelihood that a drug compendia would support an off-label dose for a drug with an FDA-approved maximum dose, and helped the client obtain stronger payer coverage with a compendia submission.
A biopharma company engaged Magnolia to develop a value story for an orphan-designated treatment for an auto-immune disorder that was in Phase III development. The company’s product had a novel mechanism of action in comparison to the existing agents in development and would be the first new agent for the disease in years.